In a research report released Wednesday, William Blair analyst Amanda Murphy reiterated an Outperform rating on shares of Illumina, Inc. (NASDAQ:ILMN), following the company’s preliminary …
In a research report sent to investors, William Blair analyst Amanda Murphy maintained an Outperform rating on Illumina (NASDAQ:ILMN), as the company reported fourth-quarter …
In a research report issued today, William Blair analyst Amanda Murphy reiterated a Market Perform rating on Pacific Biosciences (NASDAQ:PACB). No price target …
In a research report issued today, William Blair analyst Amanda Murphy reiterated a Market Perform rating on Quest Diagnostics (NYSE:DGX). No price target …
In a research report issued today, William Blair analyst Amanda Murphy maintained an Outperform rating on Myriad Genetics (NASDAQ:MYGN). No price target was …
In a research report issued today, William Blair analyst Amanda Murphy upgraded shares of Foundation Medicine (NASDAQ:FMI) to Outperform rating. No price target was …
In a research report issued today, William Blair analyst Amanda Murphy maintained a Market Perform rating on Pacific Biosciences (NASDAQ:PACB), ahead of the company’s …
In a research report issued today, William Blair analyst Amanda Murphy maintained a Market Perform rating on Bio-Reference Laboratories (NASDAQ:BRLI). No price target …
In a research report issued today, William Blair analyst Amanda Murphy maintained an Outperform rating on Myriad Genetics (NASDAQ:MYGN), following travels with management, …
In a research report issued today, William Blair analyst Amanda Murphy reiterated an Outperform rating on Illumina (ILMN) with a $200 fair value, following recent investor meeting with CEO Jay Flatley, …